Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Total Non-Current Liabilities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $117.9 million as the latest value for Q3 2025.

  • Quarterly Total Non-Current Liabilities fell 0.73% to $117.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $117.9 million through Sep 2025, down 0.73% year-over-year, with the annual reading at $130.0 million for FY2024, N/A changed from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $117.9 million at TScan Therapeutics, down from $121.7 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $130.0 million in Q4 2024, with the low at $20.7 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $82.3 million, with a median of $99.6 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities plummeted 31.99% in 2022, then soared 511.11% in 2023.
  • Over 5 years, Total Non-Current Liabilities stood at $27.2 million in 2021, then surged by 265.78% to $99.6 million in 2022, then rose by 22.89% to $122.4 million in 2023, then increased by 6.21% to $130.0 million in 2024, then dropped by 9.3% to $117.9 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $117.9 million, $121.7 million, and $122.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.